Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
4.570
-2.160 (-32.10%)
At close: May 15, 2026, 4:00 PM EDT
4.520
-0.050 (-1.09%)
After-hours: May 15, 2026, 7:58 PM EDT

Aardvark Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22
100286---
Market Cap Growth
-31.83%----
Enterprise Value
55.96176.3000
Last Close Price
4.5713.13---
PE Ratio
--4.48---
PB Ratio
1.691.29---
P/TBV Ratio
0.441.16---
P/FCF Ratio
--5.28---
P/OCF Ratio
--5.29---
EV/EBITDA Ratio
--2.81---
EV/EBIT Ratio
--2.81---
EV/FCF Ratio
--3.25---
Debt / Equity Ratio
-00.000.010.01
Debt / EBITDA Ratio
0.00-0.01-0.03-0.02-0.02
Debt / FCF Ratio
0.00-0.01-0.04-0.03-0.04
Net Debt / Equity Ratio
-0.40-0.49-19.780.280.57
Net Debt / EBITDA Ratio
1.221.753.201.331.39
Net Debt / FCF Ratio
1.472.024.011.692.72
Quick Ratio
7.8610.4314.957.2327.07
Current Ratio
8.0610.6115.057.5027.72
Return on Equity (ROE)
-31.26%-32.63%-29.51%-57.47%-84.88%
Return on Assets (ROA)
-69.26%-64.44%-51.76%-54.34%-67.81%
Return on Invested Capital (ROIC)
2187.64%3392.37%3104.22%2620.14%-7237.58%
Return on Capital Employed (ROCE)
-77.18%-70.00%-55.75%-58.58%-70.31%
Earnings Yield
-47.59%-22.32%---
FCF Yield
-42.06%-18.95%---
Buyback Yield / Dilution
-245.54%-391.06%-0.89%-1.78%-
Total Shareholder Return
-245.54%-391.06%-0.89%-1.78%-
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q